Go Pro

Gamco Investors INC. ET AL Has $26.60 Million Stock Position in Henry Schein, Inc. $HSIC

Henry Schein logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Gamco Investors trimmed its Henry Schein stake by 4.9% in the first quarter, but still held 360,949 shares valued at about $26.6 million. Institutional investors overall remain heavily involved, owning 96.62% of the company.
  • Analyst opinions are mixed, with Henry Schein carrying a consensus Hold rating and an average price target of $88.62. Recent calls ranged from Morgan Stanley’s underweight view to BTIG’s upgrade to buy.
  • The company reported better-than-expected quarterly results, posting EPS of $1.32 versus the $1.20 estimate and revenue of $3.37 billion. Shares were up 1.1% in Friday trading, and a director also bought 10,000 shares in May.
  • Five stocks to consider instead of Henry Schein.

Gamco Investors INC. ET AL lowered its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 4.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 360,949 shares of the company's stock after selling 18,447 shares during the period. Gamco Investors INC. ET AL owned 0.32% of Henry Schein worth $26,602,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein during the second quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the 2nd quarter valued at $27,000. Flagship Harbor Advisors LLC acquired a new position in Henry Schein during the fourth quarter worth $30,000. Federated Hermes Inc. acquired a new position in Henry Schein during the fourth quarter worth $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Henry Schein in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 96.62% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HSIC shares. Morgan Stanley reissued an "underweight" rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. BTIG Research raised shares of Henry Schein from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a research report on Thursday, June 11th. Robert W. Baird set a $97.00 price target on Henry Schein in a research note on Wednesday, May 6th. UBS Group reissued a "neutral" rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of Henry Schein in a research note on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Henry Schein presently has a consensus rating of "Hold" and an average price target of $88.62.

Get Our Latest Analysis on HSIC

Henry Schein Stock Up 1.1%

HSIC opened at $85.47 on Friday. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.34. The firm has a market capitalization of $9.74 billion, a P/E ratio of 25.82, a PEG ratio of 1.63 and a beta of 0.81. The company's 50-day moving average is $80.98 and its 200 day moving average is $78.04. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Insider Activity

In other Henry Schein news, Director William K. Daniel bought 10,000 shares of Henry Schein stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the completion of the acquisition, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.89% of the stock is currently owned by corporate insiders.

Henry Schein Profile

(Free Report)

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

Recommended Stories

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Henry Schein Right Now?

Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines